Preclinical drug evaluation using human inflammatory disease models including RA, IBD, psoriasis and MS
Mice with Humanized drugable gene targets offer an ideal platform for preclinical efficacy testing
Our high quality Services include scientific consulting, efficacy studies, histological and molecular assays
Development of new animal models of human disease, partner of choice in large-scale European research projects
Biomedcode is a Contract Research Organisation (CRO) providing full preclinical drug evaluation services to the pharmaceutical industry using a unique collection of proprietary mouse models of human inflammatory diseases. With a primary focus on anti-TNF therapeutics, Biomedcode’s Tg197 humanized animal model of Rheumatoid Arthritis was instrumental in demonstrating the therapeutic efficacy of Infiximab (Remicade®) currently one of the most successful anti-TNF therapeutics.
Newsletters
April 2014 - Preclinical efficacy studies on inflammation- Latest NEWS
January 2014 - New Psoriatic Preclinical Evaluation Platform